News

Resmetirom reduces cardiovascular and liver risk markers in MASH patients, with 49% achieving significant liver stiffness improvement within nine...

TG Therapeutics' ublituximab meets primary endpoint in Phase 3 RMS trial, enabling single-visit initiation dosing versus competitors.

Sacituzumab tirumotecan plus pembrolizumab cuts NSCLC progression risk by 65% in OptiTROP-Lung05 trial, with median PFS not reached versus...

Zenas BioPharma files BLA for obexelimab in IgG4-Related Disease with 56% flare reduction versus placebo over 52 weeks.

Rezdiffra reduces cardiovascular and liver risk markers in MASH patients, with significant reductions in Lp(a) and portal hypertension probability...

Spevatamig Plus Chemotherapy shows 52.4% response rate in pancreatic cancer, more than doubling historical chemotherapy-alone outcomes in Phase 2...

Ublituximab single-infusion dosing achieves bioequivalence target in Phase 3 ENHANCE trial with lower infusion-related reaction rates than prior studies.

Apogee's zumilokibart achieves 65.9% EASI-75 response in Phase 2 atopic dermatitis trial, with fewer injections than current standards.

Zenas BioPharma submits BLA for obexelimab in IgG4-Related Disease, showing 56% flare reduction over 52 weeks with p=0.0005 across...

Guselkumab becomes first IL-23 inhibitor with FDA-approved label for halting structural joint damage in psoriatic arthritis, backed by Phase...